Friday, October 14, 2005

Lohocla: Addressing Addictive Disorders

Lohocla Research Corp., is a development stage company focused on the therapy and diagnosis of pain, psychiatric and addictive disorders. The lead product, a patent protected novel compound, has demonstrated biological activity in animals for pain, anxiety and alcohol dependence. Preliminary toxicology and pharmacology studies indicate the compound (DCUK) will be orally effective and at doses that will not induce adverse behavioral stimulation. Lohocla management consists of Dr. Boris Tabakoff, Chair of Pharmacology at the University of Colorado Health Sciences Center, Dr. Vivian Dullien, founder of Biex, a venture backed biomedical company and Emelia Johnson, CFO. Lohocla is currently supported by Phase II SBIR grants and is seeking venture capital to fund preclinical toxicology and early Phase I clinical studies. Lahocla has completed the proprietary protection, proof of concept of biological activity in animal models, pilot manufacturing at Hauser and is poised to shortly start FDA studies.


job opportunitya said...

Incredible blog. I admired your site and I will be
back once again to view it! I use much of my spare
time searching for blogs like yours.
I beg of you, just check out my risk of plastic surgery blog.

job opportunitya said...

Unusual blog. I liked the site its from so much I
have to visit it again! I surf the web for blogs like
yours in my spare time.
I will give you access to jump to my plastic surgery san diego blog.